Skip to content

Forsythiaside B alleviates DOX-induced myocardial injury by enhancing the interaction between HSP90AA1 and CYP1A1 to inhibit ferroptosis.

Aug 2026 · Translational Research: The Journal of Laboratory and Clinical Medicine · Vol 297, pp. 34-54 · 0 citations · 50 references
Medicine

TL;DR

FTB enhances the interaction between HSP90AA1 and CYP1A1 and CYP1A1 to inhibit ferroptosis, thereby alleviating DOX-induced myocardial damage and presents a highly promising therapeutic strategy for the treatment of DIC.

Abstract

Background

Doxorubicin (DOX) is a potent anti-tumor drug that is commonly associated with cardiotoxic reactions (DIC) during its use. Ferroptosis in cardiomyocytes is one of the key pathogenic mechanisms of this toxic reaction. Forsythiaside B (FTB) has been proven to have cardioprotective effects, but its role and potential mechanism in DIC remain unknown.

Methods

The DOX treatment was applied to mouse and neonatal rat cardiomyocytes (NRCMs) to establish in vivo and in vitro models of DIC, in order to verify the cardioprotective effect of FTB. Meanwhile, the molecular targets of FTB were determined through proteomics, molecular docking, and molecular dynamics simulations to explore the mechanism of FTB's action. Additionally, a breast cancer xenograft model was constructed by subcutaneous injection of 4T1 cells to evaluate the impact of FTB on the anti-tumor efficacy of DOX.

Results

Our study reveals that FTB inhibits DOX-induced ferroptosis and myocardial cell damage. Moreover, when DOX-induced ferroptosis was inhibited by ferroptosis inhibitor Fer-1, FTB was unable to further inhibit DOX-induced cardiomyocyte ferroptosis and injury, indicating that FTB alleviates DOX-induced myocardial cell damage by inhibiting ferroptosis. Mechanistically, FTB directly targets heat shock protein 90 alpha family class A member 1 (HSP90AA1) and cytochrome P450 1A1 (CYP1A1), enhances the interaction between HSP90AA1 and CYP1A1, and promotes the ubiquitination and degradation of CYP1A1 mediated by HSP90AA1-STUB1 complex. Overexpression of CYP1A1 and selective inhibition of HSP90AA1 weaken the inhibitory effect of FTB on ferroptosis and its cardioprotective effect against DIC. More importantly, the application of FTB does not affect the antitumor efficacy of DOX.

Conclusion

In summary, FTB enhances the interaction between HSP90AA1 and CYP1A1 to inhibit ferroptosis, thereby alleviating DOX-induced myocardial damage. This discovery presents a highly promising therapeutic strategy for the treatment of DIC.

View source

Similar papers

Open access Sep 2026

Neohesperidin Alleviates Ferroptosis in Doxorubicin-Induced Cardiotoxicity via Mettl3-m6A-Nrf2 Signaling.

Doxorubicin (DOX) has antitumor efficacy, but its clinical application is restricted by multiple side effects, especially cardiotoxicity. Neohesperidin, a flavonoid in citrus fruits, has various health benefits. The aim of this study was to explore the cardioprotective effects and mechanisms of neohesperidin against DO...

Rui-Jia Wen, Xin Dong, Hao-Wen Zhuang et al. · 0 citations
Sep 2026

Acteoside ameliorates doxorubicin-induced cardiotoxicity by suppressing ferroptosis through activation of the KEAP1/NRF2 pathway.

Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major limitation to the clinical use of DOX, highlighting the need for effective cardioprotective strategies. Although acteoside (ACT), a natural compound with antioxidant properties, has shown potential cardioprotective effects, its role in DIC, particularly in the r...

Meng Wang, Che Wang, Zhi-Hao Liu et al. · 0 citations
Aug 2026

Isoginkgetin ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via the SIRT1/NRF2 pathway.

BACKGROUND Doxorubicin-induced cardiotoxicity (DIC) poses a substantial threat to the prognosis and survival of cancer patients. Ferroptosis, mediated in part by suppression of the SIRT1/NRF2 pathway, has been identified as a critical mechanism underlying DIC. Isoginkgetin (IGK), a naturally occurring biflavonoid with...

H. Mo, Han Su, Zhenyu Zhuang et al. · 0 citations
Sep 2026

Infection-associated lipopolysaccharide aggravates doxorubicin-induced cardiotoxicity via modulation of the FOXO1-GPX4 ferroptosis pathway.

Findings indicate that DOX and LPS synergistically promote myocardial injury by activating the FOXO1/GPX4-mediated ferroptosis pathway, providing mechanistic insight into infection-associated cardiotoxicity during DOX chemotherapy.

Tao Zhang, Chu-Chu Wang, Zi-Han Nan et al. · 0 citations
Sep 2026

Methyl Jasmonate Attenuates Doxorubicin-induced Myocardial Damage Through Multifaceted Cellular and Molecular Mechanisms: An Integrated In Vitro, In Vivo Approach.

INTRODUCTION Doxorubicin (Dox) is a widely used antineoplastic drug that often causes cardiomyopathy, leading to congestive heart failure through the production of Reactive Oxygen Species (ROS) within the myocardium. This investigation examines the protective effects of Methyl Jasmonate (MeJA) against Dox-induced cardi...

Ujwal N. Katolkar, S. Surana · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.